Ayala Pharmaceuticals Inc (ADXS)

[bomba_travel]

Curious what AMGN's angle is at this point? They are the only collaboration that seems to have legs and not using them to vanish into thin air. But.. if they do value the potential of the technology, as outlined in FBG's post, what would their strategy be now? They are paying for the clinical trials, and obligated to as much as $500M in milestones after proof-of-concept, but ADXS still owns the tech and is manufacturing the vaccine (a substantial, real-time process in the case of NEO) for AMGN, no?

Do they:
1. Wait for liquidation and try to pick it up at firesale?
2. Throw some support our way and negotiate accelerated milestones, or additional stake?
3. Buy us outright at some minor premium to current MC and save money relative to future milestones (assuming we would have gotten that far)?
4. Let whatever happens happen and move on if we go belly up?

Honest questions, as I've little experience with bio/pharma partnerships where the bio is in such dire straits. I've seen #2 happen in one instance (AGEN).

Thanks in advance for the discussion!